KR102313753B1 - Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물 - Google Patents

Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물 Download PDF

Info

Publication number
KR102313753B1
KR102313753B1 KR1020210040038A KR20210040038A KR102313753B1 KR 102313753 B1 KR102313753 B1 KR 102313753B1 KR 1020210040038 A KR1020210040038 A KR 1020210040038A KR 20210040038 A KR20210040038 A KR 20210040038A KR 102313753 B1 KR102313753 B1 KR 102313753B1
Authority
KR
South Korea
Prior art keywords
formula
plk1
compound
mmol
ptm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020210040038A
Other languages
English (en)
Korean (ko)
Inventor
최시우
류수희
류지훈
손산하
이화진
김성훈
남보아스
민임숙
류혜국
강금영
Original Assignee
(주) 업테라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주) 업테라 filed Critical (주) 업테라
Application granted granted Critical
Publication of KR102313753B1 publication Critical patent/KR102313753B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020210040038A 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물 Active KR102313753B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200037875 2020-03-27
KR20200037875 2020-03-27

Publications (1)

Publication Number Publication Date
KR102313753B1 true KR102313753B1 (ko) 2021-10-19

Family

ID=77892014

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020210040038A Active KR102313753B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
KR1020210040035A Active KR102337029B1 (ko) 2020-03-27 2021-03-27 Plk1 선택적 분해 유도 화합물
KR1020210040037D Granted KR20210122164A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210040037A Active KR102319264B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210040036D Granted KR20210122163A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR1020210040036A Active KR102313752B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR1020210040038D Granted KR20210122165A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
KR1020210171223A Active KR102529222B1 (ko) 2020-03-27 2021-12-02 Plk1 선택적 분해 유도 화합물

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020210040035A Active KR102337029B1 (ko) 2020-03-27 2021-03-27 Plk1 선택적 분해 유도 화합물
KR1020210040037D Granted KR20210122164A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210040037A Active KR102319264B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR1020210040036D Granted KR20210122163A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR1020210040036A Active KR102313752B1 (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR1020210040038D Granted KR20210122165A (ko) 2020-03-27 2021-03-27 Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
KR1020210171223A Active KR102529222B1 (ko) 2020-03-27 2021-12-02 Plk1 선택적 분해 유도 화합물

Country Status (6)

Country Link
US (5) US20230158158A1 (cg-RX-API-DMAC10.html)
EP (1) EP3911654A4 (cg-RX-API-DMAC10.html)
JP (2) JP7440940B2 (cg-RX-API-DMAC10.html)
KR (8) KR102313753B1 (cg-RX-API-DMAC10.html)
CN (1) CN113784969A (cg-RX-API-DMAC10.html)
WO (4) WO2021194318A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020356484A1 (en) 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
WO2023016518A1 (zh) 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法
WO2023104195A1 (zh) * 2021-12-10 2023-06-15 正大天晴药业集团股份有限公司 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法
JP2024546115A (ja) * 2021-12-10 2024-12-17 シャンドン ルイ ファーマシューティカル カンパニー リミテッド プロテインキナーゼ阻害剤及びその製造方法と応用
CN116924929A (zh) * 2022-07-08 2023-10-24 重庆圣华曦药业股份有限公司 一种碘比醇异构体的合成方法
CN115490675B (zh) * 2022-09-19 2024-11-12 安阳师范学院 季酮酸衍生物及其制备方法与应用
CN120603831A (zh) * 2022-11-29 2025-09-05 厄普特拉株式会社 具有增加的刚性的plk1降解诱导化合物
WO2024153110A1 (zh) * 2023-01-17 2024-07-25 北京哲源科技有限责任公司 吡唑并喹唑啉类化合物的立体异构体和氘代衍生物及应用
EP4658658A1 (en) * 2023-02-02 2025-12-10 Uppthera, Inc. Novel plk1 degradation inducing compound
CN116554044A (zh) * 2023-05-16 2023-08-08 上海师范大学 一种无氨基保护的2,6-二异丙基-4-羧基苯胺及其合成方法
KR20250058831A (ko) 2023-10-23 2025-05-02 주식회사 펩토이드 Ｐｌｋ－１의 폴로박스 도메인에 결합하는 저분자 화합물을 함유하는 항암제
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008003173A (es) * 2005-09-06 2008-03-18 Smithkline Beecham Corp Compuestos de bencimidazol-tiofeno como inhibidores de plk.
PL2125822T3 (pl) * 2006-12-21 2015-04-30 Nerviano Medical Sciences Srl Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz
CN101636399B (zh) * 2007-03-22 2012-04-18 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
BRPI0817315A2 (pt) 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
CN106543185B (zh) * 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN106977584B (zh) * 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
WO2019114770A1 (zh) 2017-12-13 2019-06-20 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
KR102127289B1 (ko) * 2018-09-18 2020-06-26 고려대학교 산학협력단 암 세포를 표적화하기 위한 plk 선택적 형광 프로브 화합물 및 이를 포함하는 plk 검출용 형광 센서
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
CN109879877B (zh) 2019-03-04 2021-08-10 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications 521 (2020) 833-839
ChemMedChem 2009, 4, 1806-1809

Also Published As

Publication number Publication date
KR102337029B1 (ko) 2021-12-09
EP3911654A4 (en) 2022-05-11
KR20210150341A (ko) 2021-12-10
US20230372498A1 (en) 2023-11-23
JP2022539579A (ja) 2022-09-12
JP2023171659A (ja) 2023-12-01
WO2021194318A1 (en) 2021-09-30
WO2021194320A1 (en) 2021-09-30
EP3911654A1 (en) 2021-11-24
KR20210122165A (ko) 2021-10-08
US20230203006A1 (en) 2023-06-29
US20230104076A1 (en) 2023-04-06
JP7440940B2 (ja) 2024-02-29
CN113784969A (zh) 2021-12-10
KR20210122164A (ko) 2021-10-08
US12403198B2 (en) 2025-09-02
WO2021194319A1 (en) 2021-09-30
KR102313752B1 (ko) 2021-10-19
US20230159515A1 (en) 2023-05-25
KR20210122162A (ko) 2021-10-08
WO2021194321A1 (en) 2021-09-30
US11833208B2 (en) 2023-12-05
KR20210122163A (ko) 2021-10-08
KR102319264B1 (ko) 2021-11-01
KR102529222B1 (ko) 2023-05-08
US20230158158A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
KR20210122165A (ko) Plk1의 선택적 분해를 유도하는 바닐린 유도체 화합물
CN113286794A (zh) Kras突变蛋白抑制剂
JP2024530495A (ja) 新規ｐｌｋ１分解誘導化合物
CN117143175A (zh) 靶向sos1蛋白泛素化调节的化合物及其制备方法和应用
US11001568B2 (en) Histone demethylase inhibitors
JP2016513656A (ja) がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
CN116410207B (zh) 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
HK1222394A1 (zh) 新的吲嗪化合物、其制备方法和包含它们的药物组合物
CN111683662B (zh) 取代嘧啶类化合物及其药物组合物和治疗方法
WO2006067224A2 (en) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
CN110386927A (zh) 组蛋白乙酰转移酶（hat）抑制剂及其用途
US20260130925A1 (en) Methods for treating cancer
CN109575013A (zh) 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
US20240000951A1 (en) Gpx4 protein degradation-inducing compound
EP4602043A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
KR20220044753A (ko) 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
KR20220034181A (ko) 테트라하이드로이소퀴놀린 화합물
KR102909254B1 (ko) Gpx4 단백질 분해 유도 화합물
KR102574152B1 (ko) Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
CN112661661A (zh) 具有hsp90抑制活性的新型化合物或其药学上可接受的盐及其医疗用途
CN119080738A (zh) 一种含肟结构的gspt1蛋白降解剂及其制备方法和应用
CN119462554A (zh) 一种hdac抑制剂及其制备、用途
WO2011092505A1 (en) S100 protein binding interaction inhibitors

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000